The work provides accessible definitions of the core elements of an estimand which will help aid understanding and should ease the use of the estimand framework across the range of stakeholders 8/8

A new paper by @suziecro.bsky.social and colleagues will help in this regard. Working with public partners, they developed a practical tool to explain the attributes of an estimand in an accessible manner 7/8
trialsjournal.biomedcentral.com/articles/10....

However, the technical language around estimands makes it hard to discuss the concept with patients and public (and indeed with many researchers and clinicians). 6/8

Kahan et al provide a useful introduction to the estimand approach and to the different terms/approaches used: 5/8
www.bmj.com/content/384/...

We may want to know how effective the treatment was in all patients allocated to it (this is called a “treatment policy” estimand strategy); or only in those patients who received it as planned (called a “principal stratum” approach) or some other variation. 4/8

“Intercurrent events” are post-randomisation events (eg discontinuation of treatment or treatment switching) and the estimand describes precisely how these events will be handled in the analysis. 3/8

An #estimand is effectively a more precise specification of the research question(s) and how the treatment effect is to be estimated (hence estimand). It also specifically describes how so called “intercurrent events” will be handled in the analysis. 2/8

The world’s largest and longest clinical trial in critical care, SuDDICU found a significant reduction in hospital-acquired infection in critically ill patients on mechanical ventilation, when given antibiotics preventatively before a new infection can develop.

Recruitment has begun for a new National Statistician (£200k). Important role as the strategic head of the UK statistical system. There is less operational work as there is now a Perm Sec for ONS. So they are seeking an ‘internationally recognised leader in statistics’
www.saxbam.com/appointment/...

Bigirumurame et al also published a useful review of SMART trials and highlighted the need for accurate reporting 7/7
www.sciencedirect.com/science/arti...

Kidwell & Almirall wrote a short primer paper on the design 6/7
jamanetwork.com/journals/jam...

They have also be used in scenarios where one might begin with testing less costly or less intensive treatment strategies in the first phase and stepping up to testing more intensive strategies only if there is lack of response 5/7

The SMART design is typically more used in chronic conditions where response can be measured over time and different interventions/doses/sequences are available should individuals not respond to their first line allocated intervention 4/7

These designs are often seen as attractive to patients as the intervention they receive can be changed if they see no improvement 3/7